{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:15:30Z","timestamp":1785842130086,"version":"3.56.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.ygyno.2011.09.019","type":"journal-article","created":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T14:49:57Z","timestamp":1318862997000},"page":"48-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study"],"prefix":"10.1016","volume":"124","author":[{"given":"Bradley J.","family":"Monk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Blessing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daron G.","family":"Street","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Y.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martee L.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.09.019_bb0005","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D'Angelo","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0010","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/cncr.2820710440","article-title":"Prognostic factors in early stage uterine sarcoma","volume":"71","author":"Major","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0015","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2005.01.041","article-title":"Systemic therapy for advanced uterine sarcoma: a systematic review of the literature","volume":"97","author":"Kanjeekal","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0020","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/IGC.0b013e3181acae50","article-title":"Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience","volume":"19","author":"Mahdavi","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0025","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1039\/b808331m","article-title":"Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem","volume":"26","author":"Cuevas","year":"2009","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0120","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/11202860-000000000-00000","article-title":"Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer","volume":"70","author":"Carter","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0035","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A review of trabectedin (ET-743): a unique mechanism of action","volume":"9","author":"D'Incalci","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0040","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0050","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0055","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X","article-title":"Optimal flexible designs in phase II clinical trials","volume":"17","author":"Chen","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0060","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ygyno.2003.11.023","article-title":"Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study","volume":"92","author":"Look","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0065","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0090-8258(02)00136-1","article-title":"Gynecologic Oncology Group Study. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"89","author":"Gallup","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0080","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ygyno.2004.11.036","article-title":"Gynecologic Oncology Group. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"96","author":"Sutton","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"no. 15_Suppl.","key":"10.1016\/j.ygyno.2011.09.019_bb0125","doi-asserted-by":"crossref","first-page":"10028","DOI":"10.1200\/jco.2010.28.15_suppl.10028","article-title":"Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose","volume":"28","author":"Judson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0090","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ygyno.2006.04.025","article-title":"Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma","volume":"102","author":"Tewari","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0095","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ygyno.2010.01.040","article-title":"Assessment of tumor response as a surrogate endpoint of survival in recurrent\/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study","volume":"117","author":"Rose","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0100","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/0002-9378(92)91671-V","article-title":"Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"166","author":"Sutton","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0105","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1006\/gyno.1999.5463","article-title":"Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study","volume":"74","author":"Sutton","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00000421-200008000-00009","article-title":"Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study","volume":"23","author":"Miller","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.09.019_bb0115","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1006\/gyno.1996.0289","article-title":"Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"63","author":"Thigpen","year":"1996","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581100789X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581100789X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:29:37Z","timestamp":1758770977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581100789X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S009082581100789X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.09.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}